21567-18-0

Basic information

• Product Name: 4-(4-Chlorophenoxy)phenol
• Synonyms: 4-(4-Chlorophenoxy)phenol;4-(4-CHLOROPHENOXY)PHENOL,99.5%;4-Hydroxy-4-chloro-diphenylether;4-(4-Chlorophenyloxy)phenol;4-Chloro-4'-hydroxydiphenyl ether;p-(p-Chlorophenoxy)phenol;4-(4-Chlorophenoxy)
• CAS NO: 21567-18-0
• Molecular Formula: C₁₂H₉ClO₂
• Molecular Weight: 220.65
• EINECS: 1312995-182-4
• Product Categories: Organic Building Blocks;Oxygen Compounds;Phenols
• Mol File: 21567-18-0.mol

Chemical Properties

• Melting Point: 80-85 °C
• Boiling Point: 169°C/2.5mmHg(lit.)
• Flash Point: 161.801 °C
• Appearance: /
• Density: 1.295 g/cm³
• Vapor Pressure: 3.43E-05mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(4-Chlorophenoxy)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Chlorophenoxy)phenol(21567-18-0)
• EPA Substance Registry System: 4-(4-Chlorophenoxy)phenol(21567-18-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41-43
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 21567-18-0(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow solid

InChI:InChI=1/C12H9ClO2/c13-9-1-5-11(6-2-9)15-12-7-3-10(14)4-8-12/h1-8,14H

Upstream product

• 352-33-0 1-Chloro-4-fluorobenzene 
• 123-31-9 hydroquinone 
• 106-39-8 bromochlorobenzene 
• 150-76-5 4-methoxy-phenol 
• 139-59-3 4-phenoxyanilin 
• 637-87-6 1-Chloro-4-iodobenzene 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 106-48-9 4-chloro-phenol 
• 459-57-4 4-fluorobenzaldehyde 
• 61343-99-5 4-(4'-chlorophenoxy)benzaldehyde 
• 205381-05-1 4-(4-chlorophenoxy)phenyl acetate 
• 40843-46-7 4-(4-chlorophenoxy)anisole 

Downstream Products

• 155291-35-3 2-chloro-4-(4-chloro-phenoxy)-phenol 
• 51337-71-4 2-[4-(4'-chlorophenoxy)-phenoxy]-propionic acid-2-methylpropyl ester 
• 51337-70-3 2-[4-(4-Chloro-phenoxy)-phenoxy]-propionic acid butyl ester 
• 66860-94-4 2-[4-(4-Chloro-phenoxy)-phenoxy]-propionic acid sec-butyl ester 
• 51318-38-8 (E)-4-[4-(4-Chloro-phenoxy)-phenoxy]-3-methyl-but-2-enoic acid ethyl ester 
• 51337-98-5 2-[4-(4-Chloro-phenoxy)-phenoxy]-dodecanoic acid ethyl ester 
• 40843-13-8 4-(4-Chlorphenoxy)-α-phenoxy-laurinsaeure 
• 51337-72-5 2-[4-(4-Chloro-phenoxy)-phenoxy]-propionic acid hexyl ester 
• 51337-79-2 2-[4-(4-Chloro-phenoxy)-phenoxy]-propionic acid benzyl ester 
• 51375-91-8 (E)-4-[4-(4-Chloro-phenoxy)-phenoxy]-3-methyl-but-2-enoic acid isopropyl ester 
• 58291-71-7 1,3-Dichloro-2-[4-(4-chloro-phenoxy)-phenoxy]-5-nitro-benzene 
• 51337-99-6 4-Amino-2-[4-(4-chloro-phenoxy)-phenoxy]-butyric acid 
• 66860-95-5 2-[4-(4-Chloro-phenoxy)-phenoxy]-propionic acid 1-methyl-hexyl ester 
• 51337-78-1 2-[4-(4-Chloro-phenoxy)-phenoxy]-propionic acid cyclopentyl ester 

Relevant articles and documents

PROCESS FOR PREPARING 4- { (S) -2- (4-(4-CHLOROPHENOXY) PHENOXYMETHYL) PYRROLIDIN-1-YL) } BUTYRIC ACID AND SALTS THEREOF

The present invention relates to a process for preparing 4-{(S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl}butyric acid and its salts.

Development of a scalable synthetic process for DG-051B, a first-in-class inhibitior of LTA4H

DG-051B is a first-in-class small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), currently in Phase II clinical development for the prevention of heart attack. Process optimization led from a linear seven-step synthetic procedure to a convergent

BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION

The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders. The compounds have general formula Ψ: An example is

ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES

Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia

PROCESS FOR THE PRODUCTION OF ANTIDIABETIC OXAZOLIDINEDIONES

The present invention provides a convergent process for the preparation of a family of antidiabetic phenoxy-substituted phenoxybenzyl oxazolidinediones shown as structure I. The compounds are selective PPAR gamma partial agonists (SPPARM's), which are use

FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY

Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obes

Selective displacement of aryl fluorides with hydroquinone: Synthesis of 4-phenoxyphenols

The selective displacement of a variety of aryl fluorides with hydroquinone has been achieved to give substituted 4-phenoxyphenols 3. In some cases the addition of 18-crown-6 resulted in a significant rate enhancement, and the reactions could be carried out at lower temperature. One of these derivatives, 3a (X = Cl) was converted to 2-propyl-4-(4-chlorophenoxy)phenol 2a, a precursor to the PPARγ receptor agonist 1.

ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES

Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones of formula (I) are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

A series of 5-aryl thiazolidine-2,4-diones containing 4-phenoxyphenyl side chains was designed, synthesized, and evaluated for PPAR agonist activities. One such compound 28 exhibited comparable levels of glucose correction to rosiglitazone in the db/db mouse type 2 diabetes animal model.

5-Aryl thiazolidine-2,4-diones: Discovery of PPAR dual α/γ agonists as antidiabetic agents

A novel series of 5-aryl thiazolidine-2,4-diones based dual PPARα/γ agonists was identified. A number of highly potent and orally bioavailable analogues were synthesized. Efficacy study results of some of these analogues in the db/db mice model of type 2 diabetes showed them superior to rosiglitazone in correcting hyperglycemia and hypertriglyceridemia.